Acumen Pharmaceuticals annual return on equity
2021
2022
2023
2024
2025
Acumen Pharmaceuticals Return on Equity (ROE) Growth & History (ABOS)
Acumen Pharmaceuticals's return on equity was −96.20% for fiscal 2025.
View full Acumen Pharmaceuticals company overviewAcumen Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −96.20% | −50.60 pp |
| 2024 | 2024-12-31 | −45.60% | −22.62 pp |
| 2023 | 2023-12-31 | −22.98% | −2.28 pp |
| 2022 | 2022-12-31 | −20.71% | +76.69 pp |
| 2021 | 2021-12-31 | −97.40% | — |
Acumen Pharmaceuticals quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −45.21% | −15.17 pp |
| Q1 2026 | 2026-03-31 | −26.26% | −9.19 pp |
| Q4 2025 | 2025-12-31 | −30.73% | −12.11 pp |
| Q3 2025 | 2025-09-30 | −25.16% | −12.25 pp |
| Q2 2025 | 2025-06-30 | −30.04% | −21.93 pp |
| Q1 2025 | 2025-03-31 | −17.07% | −11.45 pp |
| Q4 2024 | 2024-12-31 | −18.62% | −12.59 pp |
| Q3 2024 | 2024-09-30 | −12.91% | −7.14 pp |
| Q2 2024 | 2024-06-30 | −8.12% | −1.44 pp |
| Q1 2024 | 2024-03-31 | −5.62% | +0.52 pp |
| Q4 2023 | 2023-12-31 | −6.03% | +0.65 pp |
| Q3 2023 | 2023-09-30 | −5.77% | −0.46 pp |
| Q2 2023 | 2023-06-30 | −6.67% | −1.87 pp |
| Q1 2023 | 2023-03-31 | −6.15% | −2.01 pp |
| Q4 2022 | 2022-12-31 | −6.68% | −3.03 pp |
| Q3 2022 | 2022-09-30 | −5.31% | +0.82 pp |
| Q2 2022 | 2022-06-30 | −4.80% | — |
| Q1 2022 | 2022-03-31 | −4.14% | — |
| Q4 2021 | 2021-12-31 | −3.64% | — |
| Q3 2021 | 2021-09-30 | −6.13% | — |
Acumen Pharmaceuticals return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Acumen Pharmaceuticals's return on equity increased from −97.40% to −96.20%, a change of +1.19 percentage points. The latest reported quarter, Q2 2026, shows −45.21%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acumen Pharmaceuticals source filings ↗